Immunovant CFO Tiago Girao sells $188,271 in shares

Immunovant CFO Tiago Girao made a sale of 6,606 shares of the company's stock on October 28, 2026. The transaction totaled $188,271, with each share sold between $28.34 and $28.50. This was a mandated sale to cover tax obligations related to the vesting and settlement of restricted stock units. The sale does not reflect Girao's discretionary decision.

Currently, each share of Immunovant stock trades at $29.17, marking an 18% increase over the past year, though analysis indicates the shares may be slightly overvalued. Post the sale, Girao still holds 234,192 shares of the company. The shares sold were part of 13,024 RSUs that vested on October 21, 2026, originally granted on May 1, 2025.

Immunovant, valued at $6.1 billion, boasts a robust balance sheet with more cash than debt and maintains a strong financial health rating. Investors can further explore the company's performance through InvestingPro's additional ProTips.